Glofitamab with chemo for Richter syndrome
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called glofitamab combined with standard chemo-immunotherapy (rituximab or obinutuzumab plus CHOP) for people with Richter syndrome, an aggressive lymphoma that arises from CLL. The goal is to see if the combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have Richter syndrome (CLL that has turned into an aggressive B-cell lymphoma) proven by a biopsy.
- You must be between 18 and 80 years old.
- Your overall health status should allow you to be up and about (ECOG score 0-2).
- You need at least one measurable tumor (on CT or PET scan) or lymphoma cells in your bone marrow.
- Your blood counts (neutrophils, hemoglobin, platelets) must be at safe levels, unless due to bone marrow involvement.
- Your heart, liver, and kidney function must be adequate (heart pumping strength over 50%, kidney clearance over 40 mL/min).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four drugs for people whose chronic lymphocytic leukemia (CLL) has transformed into a more aggressive lymphoma called Richter syndrome. The goal is to see if this combination can control the cancer and improve outcomes.
This trial tests a new immunotherapy drug (mosunetuzumab) combined with standard chemotherapy (CHOP) as the first treatment for Richter's syndrome, a fast-growing lymphoma that can arise from CLL. The goal is to see if this combination helps control the disease better than standard therapy.
This trial tests a combination of two targeted drugs for people with Richter's transformation, an aggressive lymphoma that can develop from CLL. The goal is to see if this combination can help control the disease.
This study tests a combination of two oral drugs (nemtabrutinib and pembrolizumab) for people with Richter transformation, an aggressive lymphoma that develops from chronic lymphocytic leukemia. It may be an option if standard chemotherapy is not suitable or if prior treatment has stopped working.
This study tests whether adding a targeted drug called pirtobrutinib to the usual chemotherapy for Richter transformation can improve outcomes. It is a phase 3 trial, meaning it compares the new combination to the standard approach, and may help patients live longer or delay progression.
This trial tests a drug called glofitamab, alone or combined with other drugs, for people whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has changed into a faster-growing lymphoma (Richter's transformation). The goal is to see how well these treatments work and which combination might be best.
Hear when a new Richter Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.